ÂÜÀòÂÒÂ×

Mr. Porfido is a well-established biotech and pharmaceutical industry executive with over 25 years of strategic financial leadership expertise. Throughout his career, Mr. Porfido has demonstrated a track record of building and leading cross-functional teams. Collectively, he spent over 15 years at Novartis in various leadership roles, including serving as the Global Head of Finance for their Oncology Business Unit and Head of Global Finance for their Oncology Translational Medicines (OTM) Unit. He was responsible for developing its global strategic plan for a $15 billion business unit and in his OTM position he was a member of a leadership team that managed the early-stage Oncology pipeline.

Most recently, Mr. Porfido served as the Vice President, Finance for UroGen Pharma, Inc., a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. While there, he was responsible for the day-to-day operations of Finance and played a key role in the launch of the company’s first commercial product. Prior to that, he served in various roles at Novartis including U.S. Country Chief Financial Officer for its Ophthalmology Business Unit, Infectious Disease Transplant Business Unit, and U.S. Oncology Business Unit.

Mr. Porfido is a Certified Public Accountant and received his BBA in Accounting-CPA Prep from Pace University, his MBA in Finance from Farleigh Dickinson University.